694 related articles for article (PubMed ID: 26556857)
1. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
3. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
Wang J; Hendrix A; Hernot S; Lemaire M; De Bruyne E; Van Valckenborgh E; Lahoutte T; De Wever O; Vanderkerken K; Menu E
Blood; 2014 Jul; 124(4):555-66. PubMed ID: 24928860
[TBL] [Abstract][Full Text] [Related]
5. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow myeloid cells in regulation of multiple myeloma progression.
Herlihy SE; Lin C; Nefedova Y
Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow mesenchymal stem cells suppress ascitogenous hepatoma progression in BALB/c mouse through reducing myeloid-derived suppressor cells.
Su X; Zhang L; Ye J; Yang L; Li Y; Wang Y
Biomed Mater Eng; 2015; 25(1 Suppl):167-77. PubMed ID: 25538067
[TBL] [Abstract][Full Text] [Related]
10. Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes.
Jafarzadeh N; Safari Z; Pornour M; Amirizadeh N; Forouzandeh Moghadam M; Sadeghizadeh M
J Cell Physiol; 2019 Apr; 234(4):3697-3710. PubMed ID: 30317554
[TBL] [Abstract][Full Text] [Related]
11. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3.
Diao J; Yang X; Song X; Chen S; He Y; Wang Q; Chen G; Luo C; Wu X; Zhang Y
Med Oncol; 2015 Feb; 32(2):453. PubMed ID: 25603952
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways.
Guo X; Qiu W; Liu Q; Qian M; Wang S; Zhang Z; Gao X; Chen Z; Xue H; Li G
Oncogene; 2018 Aug; 37(31):4239-4259. PubMed ID: 29713056
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
14. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation.
Lee JM; Kim EK; Seo H; Jeon I; Chae MJ; Park YJ; Song B; Kim YS; Kim YJ; Ko HJ; Kang CY
Eur J Immunol; 2014 Jun; 44(6):1672-84. PubMed ID: 24659444
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
[TBL] [Abstract][Full Text] [Related]
16. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
17. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Görgün GT; Whitehill G; Anderson JL; Hideshima T; Maguire C; Laubach J; Raje N; Munshi NC; Richardson PG; Anderson KC
Blood; 2013 Apr; 121(15):2975-87. PubMed ID: 23321256
[TBL] [Abstract][Full Text] [Related]
18. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
